Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    16
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BD08 ARYOSEVEN RT BioTech Eptacog alfa - 1mg 1mg Injectable powder for solution+diluent 16,902,713 L.L
B02BD08 ARYOSEVEN RT BioTech Eptacog alfa - 1mg 1mg Injectable powder for solution+diluent L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution + solvent 34,948,930 L.L
L01FD01 ARYOTRUST BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 21,176,745 L.L
A07EC02 ASACOL B Mesalazine - 400mg 400mg Tablet, enteric coated 5,895,437 L.L
A07EC02 ASACOL B Mesalazine - 800mg 800mg Tablet 6,833,439 L.L
A07EC02 ASACOL B Mesalazine - 500mg 500mg Suppository 1,703,992 L.L
A07EC02 ASACOL B Mesalazine - 1g/100ml 1g/100ml Enema 2,748,158 L.L
A07EC02 ASACOL B Mesalazine - 1600mg 1600mg Tablet, modified release 8,454,523 L.L
A07EC02 ASACOL B Mesalazine - 1600mg 1600mg Tablet, modified release 12,310,378 L.L
C10AA05 ASCOVA G Atorvastatin (calcium) - 10mg 10mg Tablet, scored 1,126,268 L.L
C10AA05 ASCOVA G Atorvastatin (calcium) - 20mg 20mg Tablet 1,356,641 L.L
C10AA05 ASCOVA G Atorvastatin (calcium) - 40mg 40mg Tablet 1,612,611 L.L
J05AB01 ASIMPLEX G Aciclovir - 250mg 250mg Injectable lyophilised powder for solution 278,175 L.L
R03AC02 ASMALAT G Salbutamol (sulfate) - 2mg/5ml 2mg/5ml Syrup 177,899 L.L
G04BD08 ASOLFENA G Solifenacin succinate - 5mg 5mg Tablet, film coated 971,598 L.L
G04BD08 ASOLFENA G Solifenacin succinate - 10mg 10mg Tablet, film coated 971,598 L.L
R05CA ASPECTON COUGH SYRUP G Thyme soft extract - 6.69g/100ml Syrup 588,603 L.L
B01AC06 ASPI-COR G Acetylsalicylic acid - 81mg 81mg Tablet, enteric coated 690,735 L.L
B01AC06 ASPICOT G Acetylsalicylic acid - 81mg 81mg Tablet, enteric coated 353,239 L.L
B01AC06 ASPICOT G Acetylsalicylic acid - 100mg 100mg Tablet, enteric coated 403,153 L.L
B01AC06 ASPICOT G Acetylsalicylic acid - 100mg 100mg Tablet, enteric coated 134,384 L.L
B01AC06 ASPIPHAR G Acetylsalicylic acid - 100mg 100mg Tablet, enteric coated 134,384 L.L
B01AC06 ASPIRIN PROTECT B Acetylsalicylic acid - 100mg 100mg Tablet, enteric coated 146,479 L.L
N02BA01 ASPIRINE B Acetylsalicylic acid - 300mg 0.3g Tablet 80,631 L.L
N02BA51 ASPIRINE C EFFERVESCENT B Acetylsalicylic acid - 400mg, Vitamin C - 240mg Tablet, effervescent 162,605 L.L
N02BA51 ASPRIVIT G Acetylsalicylic acid - 500mg, Caffeine - 50mg, Vitamin B1 - 2mg Tablet 186,794 L.L
B01AC06 ASPROTHIN G Acetylsalicylic acid - 81mg 81mg Tablet, enteric coated 148,463 L.L
N02AJ08 ASTEFOR G Ibuprofen - 400mg, Codeine phosphate hemihydrate - 30mg Tablet, film coated 935,314 L.L
R03AC02 ASTHALIN G Salbutamol (sulfate) - 2.5mg/2.5ml 2.5mg/2.5ml Inhalation solution 325,210 L.L
    ...
    16
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025